Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 2/20 | 0.76 |
| ▸ | KDR | P35968 | 2/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.56 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.45 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6480366 | 0.84 | TEK (0.76) | TEKKDRFGFR3FGFR2EGFR | |
| SCHEMBL14214739 | 0.84 | TEK (0.82) | TEKKDRFGFR3FGFR2PTK2 | |
| SCHEMBL6492448 | 0.83 | TEK (0.75) | TEKKDRFGFR3FGFR2EGFR | |
| SCHEMBL14214552 | 0.83 | TEK (0.81) | TEKKDRFGFR3FGFR2FGFR1 | |
| SCHEMBL6598236 | 0.82 | TEK (0.73) | TEKKDRFGFR3FGFR2PTK2 | |
| SCHEMBL6480986 | 0.81 | TEK (0.74) | TEKKDRFGFR3FGFR2PTK2 | |
| SCHEMBL14214549 | 0.81 | TEK (0.77) | TEKKDRFGFR3FGFR2PTK2 | |
| SCHEMBL6479686 | 0.81 | TEK (0.89) | TEKKDRFGFR3FGFR2EGFR | |
| SCHEMBL14214554 | 0.81 | TEK (0.74) | TEKKDRFGFR3FGFR2PTK2 | |
| SCHEMBL14214551 | 0.79 | TEK (0.78) | TEKKDRFGFR3FGFR2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864255-B2 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1385833-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | Amgen Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | AMGEN INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2002083654-A1 | TRIAZINYL AMIDE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AMGEN INC. (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087908-A1 | Substituted triazinyl amide derivatives and methods of use | FLT4, FLT1, VEGFA | TEK 6/4885KDR 4/4885FGFR3 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.